Article Text

Download PDFPDF
Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer: A Meta-Analysis
  1. Xingxing Chen, MD,
  2. Haizhou Zou, MD,
  3. Huifang Li, MD,
  4. Ruifang Lin, MD,
  5. Meng Su, MD,
  6. Wenyi Zhang, MD,
  7. Yongqiang Zhou, MD,
  8. Ping Zhang, MD,
  9. Meng Hou, PhD,
  10. Xia Deng, MD and
  11. Changlin Zou, MD
  1. * Department of Chemoradiation Oncology, The First Affiliated Hospital of Wenzhou Medical University;
  2. Department of Oncology, Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou, Zhejiang, P.R. China.
  1. Address correspondence and reprint requests to Changlin Zou, MD, Department of Chemoradiation Oncology, the First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Street, Wenzhou, 325000, Zhejiang, P.R. China. E-mail: zcl19670115{at}163.com.

Abstract

Background The aim of this study was to evaluate toxicity, compliance, recurrence and the survival of weekly and triweekly cisplatin-based concomitant chemoradiation in treatment of cervical cancer.

Materials and Methods The databases were searched from 1995 until 2015 to identify eligible studies on weekly versus triweekly cisplatin chemoradiotherapy. The data were analyzed by RevMan 5.3 software.

Results A total of 5 randomized controlled trials were included in this review. Weekly cisplatin regimen significantly reduced the incidence of Hematologic toxicity. However, there was no significantly different between the 2 arms in compliance, recurrence and the survival rate (all P >0.05).

Conclusions Weekly cisplatin regimen had the similar therapeutic effect as the triweekly cisplatin regimen but with less hematologic toxicity. Therefore, we recommend the weekly cisplatin 30 to 40 mg/m2 chemoradiotherapy as the strong candidate for the optimal cisplatin dose and dosing schedule in the treatment of locally advanced cervical cancer.

  • Cervical cancer
  • Chemoradiotherapy
  • Cisplatin
  • Weekly
  • Triweekly

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.